FDA Approves First Pill to Fight Pancreatic Cancer

After decades of failed attempts, a new daily pill called daraxonrasib nearly doubles survival time for pancreatic cancer patients by targeting a protein mutation once thought "undruggable.

" The FDA approved it six months early, offering fresh hope for one of medicine's deadliest challenges.